Follow the Flow: Four Names Getting Bought, None Overbought
Four very different businesses — a healthcare conglomerate, a property-casualty insurer, an aerospace engine maker, and a pharma giant — have one thing in common right now: real money is moving into all of them, and not one is sitting at a momentum extreme. That combination is worth paying attention to. Overbought money-flow stories are chasing a crowd. Neutral money-flow stories are often still early.
Here's what we're watching, and why none of these look "priced for perfection" yet.
Johnson & Johnson $JNJ — Institutional Buyers Defending the Dip
JNJ posted a Q2 beat on both sales and profit — revenue grew 5.6% to $25.3B — and raised full-year guidance, driven by strength in its Innovative Medicine unit. Shares still dipped about 3% on the print, which is often less a verdict on the quarter than a reset in a stock that had run hard into it: JNJ is up over 50% over the trailing year.
The bigger technical story is what's happened since. Chart watchers have flagged a defended demand zone in the low $220s — the kind of level where institutional buyers have repeatedly stepped in rather than let the stock slide. Layer on the FDA's marketing authorization for JNJ's new OTTAVA robotic surgery platform — a direct shot at Intuitive Surgical's turf in soft-tissue robotics — and you have a name where the news flow and the buying have been pointing the same direction.
14-day RSI sits in the low-to-mid 50s — squarely neutral. Not stretched, not washed out.
Chubb $CB — When Buffett Buys, We Take Notice
The single loudest "money is flowing in" signal on this list: Berkshire Hathaway disclosed a $6.7 billion stake in Chubb, and shares jumped over 8% on the news. That's about as unambiguous a smart-money vote of confidence as exists in public markets — Buffett has been explicit that property-casualty insurance sits at the core of Berkshire's investment philosophy, and Chubb is the largest publicly traded name in that business globally.
Chubb's own numbers back up the case: Q1 net income came in at $2.32 billion, or $5.88 per share, and the stock has spent the last month consolidating in a tight range rather than running away from value-conscious buyers.
Readings across sources cluster in the high-40s — below the neutral 50 line, but nowhere near the sub-30 oversold zone. This is a stock resting, not retreating.
GE Aerospace $GE — Backlog Growing Faster Than the Stock Can Price It
GE Aerospace's Q2 print was about as strong as they come — orders up 17% to $16.5 billion, revenue up 24% to $12.6 billion, and adjusted EPS of $2.02, a 22% year-over-year gain. Management raised full-year guidance across revenue, profit, and cash flow for the second straight quarter. Shares still dropped roughly 5% the morning after the print — a familiar pattern for this stock, where "expensive" (it trades near 46x forward earnings) keeps colliding with "still growing."
The pullback didn't last. GE's 50-day moving average crossed above its 200-day back in mid-June — a golden cross, one of the more reliable signals that a longer-term uptrend is taking hold — and the stock has since pushed to fresh 52-week highs. The services backlog alone now sits above $170 billion, with defense backlog north of $30 billion after a string of new engine program wins. That's a multi-year runway most industrials would envy.
14-day RSI is running in the mid-50s — healthy and unstretched, even after a month where the stock is up close to 19%. Strength without the technical excess yet.
Eli Lilly $LLY — Buying Pressure Building Quietly
LLY is the steadiest mover of the four: shares extended a one-month gain past 6%, holding above both its 20-day moving average and a rising trendline. What stands out isn't the price action itself — it's the volume underneath it. On-Balance Volume, which tracks the running tally of buying versus selling pressure, has been climbing even as day-to-day share volume ran slightly below average. That's a classic sign of accumulation: fewer, larger buyers building a position rather than a crowd piling in all at once.
Lilly also announced a $2.8 billion acquisition of AtaiBeckley, its first real push into psychedelic medicine — a new therapeutic category for a company that's spent the last several years dominating obesity and diabetes care.
Also around the mid-50s — comfortably neutral, with room in either direction before any technical extreme comes into play.
Money is moving in before the technicals say it's too late to pay attention.
Four names, four different reasons for the buying — an earnings beat and a defended chart level, a Buffett-sized stake, a blowout guidance raise with a fresh golden cross, and quiet accumulation ahead of a strategic acquisition. What ties them together is what's not happening: none of them are showing the kind of RSI extremes that usually mean a move is already crowded. Worth tracking each of these in next week's issue to see whether that flow keeps building — or whether the crowd catches up first.